Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.37 |
| ▸ | CDK2 | P24941 | 13/20 | 0.37 |
| ▸ | GSK3B | P49841 | 10/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5620104 | 1.00 | TYR (0.53) | TYRITGB3ITGAVCCNE1CDK2 | |
| SCHEMBL7214900 | 0.85 | TYR (0.54) | TYRCCNE1CDK2GSK3BEGLN1 | |
| SCHEMBL5619912 | 0.85 | TYR (0.54) | TYRCCNE1CDK2GSK3BEGLN1 | |
| SCHEMBL5619910 | 0.85 | TYR (0.54) | TYRCCNE1CDK2GSK3BEGLN1 | |
| SCHEMBL6436676 | 0.83 | TYR (0.54) | TYRCCNE1CDK2GSK3B | |
| SCHEMBL6436683 | 0.83 | TYR (0.54) | TYRCCNE1CDK2GSK3B | |
| SCHEMBL7246057 | 0.78 | TYR (0.56) | TYREGLN1 | |
| SCHEMBL5619056 | 0.77 | TYR (0.52) | TYRMEN1KMT2A | |
| SCHEMBL5618879 | 0.76 | TYR (0.59) | TYRMEN1KMT2A | |
| SCHEMBL5618872 | 0.76 | TYR (0.59) | TYRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3950046-B2 | — | — | 2007-07-25 | — | — | JP | claimed |
| JP-2004509154-A | — | — | 2004-03-25 | — | — | JP | claimed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | claimed |
| EP-1318974-A2 | RESORCINOL DERIVATIVES | Pfizer Products Inc. (US) | 2003-06-18 | — | — | EP | claimed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | claimed |
| WO-2002024613-A2 | RESORCINOL DERIVATIVES | PFIZER PRODUCTS, INC. (US) | 2002-03-28 | — | — | WO | claimed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| EP-1318974-A2 | RESORCINOL DERIVATIVES | Pfizer Products Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| WO-2002024613-A2 | RESORCINOL DERIVATIVES | PFIZER PRODUCTS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | TYR 8/4885ITGB3 4730/4885ITGAV 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.